1Peet, M, Glen, I & Horrobin, DF (editors) (2006) Phospholipid Spectrum Disorders in Psychiatry and Neurology. Carnforth: Marius Press.
2Vaddadi, K (editor) (2006) Essential fatty acids and mental illness. In Int Rev Psychiatry, pp. 18, 81–186, .
3Freeman, MP, Hibbeln, JR, Wisner, KL, Davis, JM, Mischoulon, D, Peet, M, Keck, PE Jr, Marangell, LB, Richardson, AJ, Lake, J & Stoll, AL (2006) Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 67, 1954–1967.
4Rogers, PJ, Appleton, KM, Kessler, D, Peters, TJ, Gunnell, D, Hayward, RC, Heatherley, SV, Christian, LM, McNaughton, SA & Ness, AR (2007) No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 95, 000–000.
5Zanarini, MC & Frankenburg, FR (2003) Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 160, 167–169.
6Hallahan, B, Hibbeln, JR, Davis, JM & Garland, MR (2007) Omega-3 fatty acid supplementation in patients with recurrent self-harm: single-centre double-blind randomised controlled trial. Br J Psychiatry 190, 118–112.
7Buydens-Branchey, L & Branchey, M (2006) n-3 Polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J Clin Psychopharmacol 26, 661–665.
8Hamazaki, T, Sawazaki, S, Itomura, M, Asaoka, E, Nagao, Y, Nishimura, N, Yazawa, K, Kuwamori, T & Kobayashi, M (1996) The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J Clin Invest 97, 1129–1133.
9Fontani, G, Corradeschi, F, Felici, A, Alfatti, F, Migliorini, S & Lodi, L (2005) Cognitive and physiological effects of Omega-3 polyunsaturated fatty acid supplementation in healthy subjects. Eur J Clin Invest 35, 691–699.
10Richardson, AJ (2006) Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 18, 155–172.
11Freund-Levi, Y, Eriksdotter-Jonhagen, M, Cederholm, T, Basun, H, Faxen-Irving, G, Garlind, A, Vedin, I, Vessby, B, Wahlund, LO & Palmblad, J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63, 1402–1408.
12Appleton, KM, Hayward, RC, Gunnell, D, Peters, TJ, Rogers, PJ, Kessler, D & Ness, AR (2006) Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 84, 1308–1316.
13Peet, M & Horrobin, DFA (2002) dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 59, 913–919.
14Peet, M & Horrobin, DF (2002) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatry Res 36, 7–18.
15Recommendations for intake of polyunsaturated fatty acids in healthy adults (www.issfal.org.uk/).